ESPR Esperion Therapeutics, Inc.

12.00
+0  (0%)
Previous Close 12.00
Open 12.24
Price To book 1.06
Market Cap 270.64M
Shares 22,553,000
Volume 286,035
Short Ratio 14.63
Av. Daily Volume 267,113

SEC filingsSee all SEC filings

  1. 8-K - Current report 17517546
  2. 8-K - Current report 162044398
  3. 8-K - Current report 161972198
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161972158
  5. 8-K - Current report 161934071

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Top-line results due mid-2018.
Bempedoic acid (ETC-1002-040) - CLEAR Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension

Latest News

  1. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
  3. Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
  4. Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
  5. Esperion Therapeutics Inc (ESPR): Smart Money Doubles Down
  6. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
  7. Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech
  8. Esperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  9. Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
  10. Esperion Therapeutics downgraded by Citigroup
  11. ESPERION THERAPEUTICS, INC. Financials
  12. Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
  13. ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  14. ESPERION THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  15. Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
  16. Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
  17. Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
  18. Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
  19. Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target
  20. Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose

SEC Filings

  1. 8-K - Current report 17517546
  2. 8-K - Current report 162044398
  3. 8-K - Current report 161972198
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161972158
  5. 8-K - Current report 161934071
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807976
  7. 8-K - Current report 161807913
  8. 8-K - Current report 161736360
  9. 8-K - Current report 161715367
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161617550